Intravenous immunoglobulin for the treatment of childhood encephalitis
Encephalitis is a syndrome of neurological dysfunction due to inflammation of the brain parenchyma, caused by an infection or an exaggerated host immune response, or both. Attenuation of brain inflammation through modulation of the immune response could improve patient outcomes. Biological agents su...
Main Authors: | Iro, M, Martin, N, Absoud, M, Pollard, A |
---|---|
פורמט: | Journal article |
שפה: | English |
יצא לאור: |
Cochrane Collaboration
2017
|
פריטים דומים
-
Intravenous immunoglobulin treatment in childhood encephalitis (IgNiTE): a randomised controlled trial
מאת: Hill, M, et al.
יצא לאור: (2023) -
Childhood encephalitis in the United Kingdom - epidemiology, trends in hospital admissions and the role of intravenous immunoglobulin
מאת: Iro, M
יצא לאור: (2018) -
Intravenous immunoglobulin treatment for encephalitis in children aged 6 months to 16 years: the IgNiTE RCT
מאת: Iro, MA, et al.
יצא לאור: (2024) -
Intravenous immunoglobulin treatment in childhood encephalitis (IgNiTE): a randomised controlled trial
מאת: Simon Nadel, et al.
יצא לאור: (2023-11-01) -
Intravenous immunoglobulin treatment for encephalitis in children aged 6 months to 16 years: the IgNiTE RCT
מאת: Mildred A Iro, et al.
יצא לאור: (2024-04-01)